Tristan Manalac is a Senior Staff Writer at BioSpace. Based in Metro Manila, Tristan has over eight years of experience covering a range of topics within medicine and healthcare, including pharmaceuticals, healthcare technology, and alternative medicine, with a keen interest in oncology, immunotherapy, and mental health care. He has been featured in BioSpace, where he shares his insights on the evolving landscape of medical specialties and innovative treatments.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Tristan Manalac's coverage predominantly focuses on the healthcare and pharmaceutical industry, particularly FDA approvals, drug development, and related market movements. His reliance on press releases and data citations suggests a preference for fact-based reporting.
Given his focus on specific companies and regulatory developments in the pharmaceutical industry, Tristan is likely to be responsive to pitches from experts with direct knowledge of relevant drugs, therapies or regulatory processes. Additionally, he may be interested in insights into market trends impacting drug pricing or innovative approaches in drug development.
While geographic focus isn't specified, considering that pharma news often has global implications due to multinational companies involved in research and distribution of drugs worldwide would also be important when reaching out to him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Tristan Manalac
Otsuka Pharmaceuticals' Voyxact is not the only IgA nephropathy drug that can slow the decline of kidney function. Vera Therapeutics' Trutakna, which the FDA granted accelerated approval last month, showed “impressive” stabilization, analysts say.
By: Tristan Manalac
AstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.
By: Tristan Manalac
With a Phase 3 trial reducing serious and severe hypoglycemic episodes following weight loss surgery, Amylyx Pharmaceuticals plans to file for approval this year. If granted market entry, avexitide could hit peak sales of $1.7 billion worldwide, analysts estimate.
By: Tristan Manalac
The discontinuation of the uveitis study adds to Regeneron's series of clinical setbacks, including the Phase 3 failures of the Dupixent follow-up itepekimab and an investigational combo regimen for melanoma.
By: Tristan Manalac
AstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.
By: Tristan Manalac
Despite coming away with an early victory over Eli Lilly in the oral obesity face-off, analysts don’t expect Novo Nordisk’s lead to last for very long.
By: Tristan Manalac
Following a tumultuous stretch under ex-Commissioner Marty Makary, current FDA leadership is working to restore reliability, integrity and transparency to the agency—but experts say that doesn't necessarily mean an easier regulatory road for drugmakers.
By: Tristan Manalac
Not much is known about Boehringer Ingelheim's drug candidate, dubbed BI 3031185, though the asset has completed at least two other Phase 1 studies this year.
By: Tristan Manalac
The current classifications of vaccine recommendations could imply that not all shots require the consent of patients or their parents, according to Health Secretary Robert F. Kennedy Jr.
Roche, through its subsidiary Genentech, will gain access to the investigational asset HM17321, which is designed to not only elicit weight loss but also improve lean mass.
